Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) and Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.
Profitability
This table compares Jazz Pharmaceuticals and Prestige Consumer Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jazz Pharmaceuticals | 4.37% | 16.88% | 6.46% |
| Prestige Consumer Healthcare | 13.29% | 11.28% | 5.25% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Jazz Pharmaceuticals and Prestige Consumer Healthcare, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jazz Pharmaceuticals | 0 | 2 | 17 | 1 | 2.95 |
| Prestige Consumer Healthcare | 1 | 3 | 1 | 0 | 2.00 |
Insider & Institutional Ownership
89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Jazz Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
Earnings and Valuation
This table compares Jazz Pharmaceuticals and Prestige Consumer Healthcare”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jazz Pharmaceuticals | $4.27 billion | 3.47 | -$356.15 million | $2.94 | 78.37 |
| Prestige Consumer Healthcare | $1.09 billion | 2.16 | $190.30 million | $3.24 | 15.31 |
Prestige Consumer Healthcare has lower revenue, but higher earnings than Jazz Pharmaceuticals. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Jazz Pharmaceuticals beats Prestige Consumer Healthcare on 10 of the 15 factors compared between the two stocks.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare, Inc. develops, markets and distributes over-the-counter health and personal-care products. Its portfolio includes brands such as Dramamine for motion sickness, Clear Eyes for eye care, Chloraseptic for sore-throat relief, Compound W for wart removal, and Summer’s Eve for feminine care. The company’s products serve categories including eye and ear care, cough and cold relief, pain relief, digestive health, and women’s health. They are sold through retail channels such as drugstores, supermarkets, mass-market retailers and online sellers.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
